About
PTM Biosciences is dedicated to advancing personalized medicine by developing proteomics-based products and tools for disease diagnosis, disease management, and drug development. The company is developing and commercializing a technology called Post Translational Modifications Profiling, conceived at the Harvard Medical School by Dr. Yifat Merbl, a co-founder of the company. This proprietary technology uncovers the potential of protein modifications to reveal the actual physiological state of a disease and provides key information for the identification of novel drug targets, elucidation of mechanism of action of drugs, and discovery of predictive biomarkers. By measuring PTM activity from clinical samples such as blood or tumor tissue, the company generates a patient-specific, activity-based signature as a core facilitator of personalized medicine. Future developments in the company's pipeline include applying its PTM profiling platform for the analysis of liquid biopsies of melanoma and SLE patients and generating diagnostic biomarkers that can detect, predict, and monitor disease activity of these patients in order to serve as the basis for the development of novel treatments.
Q&A
- What is PTM Biosciences' primary focus?
- PTM Biosciences focuses on advancing personalized medicine through proteomics-based products and tools for disease diagnosis, management, and drug development.
- What proprietary technology does PTM Biosciences utilize?
- PTM Biosciences uses a proprietary technology called Post Translational Modifications Profiling, which was conceived at Harvard Medical School by co-founder Dr. Yifat Merbl.
- How does PTM Biosciences' technology contribute to personalized medicine?
- By measuring PTM activity from clinical samples like blood or tumor tissue, PTM Biosciences generates patient-specific, activity-based signatures to facilitate personalized medicine.
- What are PTM Biosciences' future development plans?
- PTM Biosciences plans to apply its PTM profiling platform for analyzing liquid biopsies of melanoma and SLE patients to generate diagnostic biomarkers for disease detection, prediction, and monitoring, which will serve as a basis for novel treatment development.
- When was PTM Biosciences founded?
- PTM Biosciences was founded in November 2012.
- Where is PTM Biosciences headquartered?
- PTM Biosciences is headquartered in Caesarea, Israel.
- What is the current employee count for PTM Biosciences?
- PTM Biosciences has 1-10 employees.
- In which sector does PTM Biosciences primarily operate?
- PTM Biosciences primarily operates in the Health Tech & Life Sciences sector.
Team · 2
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ptm-biosciences.com/ |
|---|---|
| linkedin.com/company/42938941 |
Identifiers & details
| Founded | 2012-11 |
|---|---|
| Employees (exact) | 1 |
Radar intelligence
Web history (Wayback)
| Domain | ptm-biosciences.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|